<DOC>
	<DOCNO>NCT00307567</DOCNO>
	<brief_summary>Booster immune memory study</brief_summary>
	<brief_title>Multicentre Booster &amp; Immune Memory Study Booster Dose GSK Biologicals ' 10-valent Pneumococcal Conjugate Vaccine Single Dose 23-valent Plain Polysaccharide Vaccine Healthy Children Aged 11-18 Mths , Previously Vaccinated Study 103488</brief_title>
	<detailed_description>Total : All 689 subject enrol study 103488 . 23PS group : Aventis Pasteurs ' 23-valent polysaccharide pneumococcal vaccine ( Pneumovax 23 ) + DTPa-HBV-IPV/Hib ; 10V group : GSK Biologicals ' 10-valent pneumococcal conjugate vaccine + DTPa-HBV-IPV/Hib</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion criterion : Male female , include , 1118 month age time vaccination previously participate study 11PNPDDIT002 receive least one dose pneumococcal conjugate vaccine primary study , free obvious health problem write informed consent obtain parent/guardian subject . Exclusion criterion : Use investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use study period . Planned administration/ administration vaccine foreseen study protocol period start one month first dose vaccine ( ) entire study period . Administration additional pneumococcal vaccine DTPa combine vaccine since study end 11PNPDDIT002 study</criteria>
	<gender>All</gender>
	<minimum_age>11 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>